ATOPIC DERMATITIS (AD)

This study tests a new medicine called GS101 against the standard treatment Dupixent for people with moderate-to-severe atopic dermatitis (eczema). About 572 adults aged 18 to 75 will receive either GS101 or Dupixent injections for up to a year. The main goal is to see if GS101 c…

This study looks at whether a pill called ivarmacitinib can help people with moderate-to-severe eczema (atopic dermatitis) who didn't get better after using other injectable medications. About 300 adults will take the pill for 16 weeks, and doctors will check if their skin rash a…

This early-phase study tests an experimental drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The main goal is to check safety and how the body processes the drug. Researchers will also look at early signs of effecti…

This study tests a new drug called SIM0278 in 184 adults with moderate to severe atopic dermatitis (eczema). Participants will receive one of three doses of the drug or a placebo to see if it reduces skin redness, itching, and rash. The main goal is to measure improvement in ecze…

This study tests how well the approved eczema drug ivarmacitinib works and how safe it is in real-world use. About 1,000 people aged 12 to 75 with moderate-to-severe atopic dermatitis will take part. Researchers will track itch relief, skin clearing, and how different treatment p…

This study tests whether a cream called crisaborole works better than a placebo for treating mild to moderate eczema (atopic dermatitis). About 270 people aged 12 to 50 will apply the cream twice daily for four weeks. The goal is to see if the cream clears or nearly clears the sk…

This study tests a medicated foam (OPA-15406) for children and infants with atopic dermatitis (eczema). About 198 kids will use the foam daily for 4 weeks to see if it clears or nearly clears their skin. The trial is for children with mild to moderate eczema covering 5-40% of the…

This study tests a medicated foam (1% OPA-15406) against a placebo foam in adults with mild-to-moderate atopic dermatitis (eczema). About 156 participants will apply the foam daily for 4 weeks. The goal is to see if the foam can clear or nearly clear skin symptoms like redness an…

This study tests a new injection called Stapokibart for adults with moderate-to-severe atopic dermatitis (eczema). Researchers will monitor 1,000 participants for side effects and how well the drug controls their skin condition. The goal is to see if this treatment is safe and ef…

This study tests whether a newer cream (crisaborole) works as well as a standard cream (tacrolimus) for children aged 2–18 with mild to moderate eczema. About 66 kids will use one of the two creams twice daily for 28 days. The main goal is to see how many achieve clear or almost …

This study will use a special headband to measure brain activity in 20 adults with mild to moderate eczema (atopic dermatitis). Researchers want to see if a marketed skin product changes brain waves related to pain, itching, and discomfort compared to plain water. The goal is to …

This study will follow 50 Costa Rican adults with moderate-to-severe atopic dermatitis (eczema) who are already receiving advanced treatments like dupilumab or JAK inhibitors as part of their routine care. Researchers will collect data from regular doctor visits to see how sympto…

This study looks at the best time to moisturize for teens aged 12-18 with eczema. Participants will apply moisturizer while in the shower or bath for one month, then after towel drying for another month. Researchers will measure skin hydration, itch, and eczema severity to see wh…